Inclusion Criteria:  HIV-1 infection, coinfection HIV-1/HIV-2 possible Age≥18 years old Current dual therapy unchanged for the last 6 months with Dolutegravir/ Lamivudine or Dolutegravir / Rilpivirine or Darunavir/r / Lamivudine If a genotype is available in the patient medical history; virus must be susceptible to all on going dual therapy. If no ARN genotype available, the patients can be included in the study Viral load (VL) < 50 c/mL in the past twelve months, with at least 3 VL measurements including screening; only one blip < 200 c/mL is authorized in the 6-12 previous months CD4 T cells > 250/mm3 at W-4 Estimated glomerular filtration rate > 60 mL/min (CKD-EPI method) AST et ALT < 3N Haemoglobin > 10 g/dL Platelets > 100 000/mm3 For women of childbearing age, negative pregnancy plasmatic test at W-4 and agree to use efficacy contraception during the study Commitment to use condom prevention and protection during sexual intercourse for the duration of the trial. Social security system coverage (including State Medical Aid-AME, if EC approves it) Informed consent form signed  Exclusion Criteria:  Infection by HIV-2 Chronic and active Viral B Hepatitis with positive antigen HBs Chronic and active Viral C Hepatitis with treatment expected in the next 48 weeks Concomitant treatment using interferon, interleukins, any other immune-therapy or chemotherapy, antivitamin K+ with co-treatment by booster Concomitant prophylactic or curative treatment for an opportunistic infection All conditions (use of alcohol, drugs, etc.) judged by the investigator to possibly interfere with study protocol compliance, observance and/or study treatment tolerance Pregnant or breast feeding women Subjects under "sauvegarde de justice" (judicial protection due to temporarily and slightly diminished mental or physical faculties), or under legal guardianship